With the combined use of the four methylation markers that exhibited differential methylation in cancer (APC, E-cadherin, hMLH1 and TIMP3), 33 (55%) patients had methylated serum DNA detected in at least one of these markers. This evidence concerns the gene CDH1 and cancer.